Will the Phase 2/Phase 3 trial "A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma" reach primary completion on or before Feb 1, 2028?

Resolves Yes if ClinicalTrials.gov record NCT07389616 (Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) shows an actual primary completion date on or before Feb 1, 2028. Registered date at generation: Feb 1, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Feb 1, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.